What is BMEA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.10B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BMEA?

P/E (TTM) is n/a and 52-week range is $0.87 to $2.24 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BMEA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BMEA?

The company profile lists net income (TTM) near $-36M, EPS (TTM) near $-0.50 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Biomea Fusion Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Carlos, California, US, 72.3M shares outstanding, ISIN US09077A1060 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Biomea Fusion Inc

$BMEA

Health Care · Biotechnology

IR Run Scenarios

$1.42

+3.65%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 41 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.

Employees

Website

www.biomeafusion.com/

IPO

2021-04-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)